予防ワクチンの世界市場レポート2025年

予防ワクチン市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は6.9%で、1,064億7,000万米ドルに成長します。この成長予測には、ワクチン研究費の急増、感染症負担の増加、カスタムメイド・ワクチン需要の増加、政府支援の拡大、最先端ワクチン技術の採用拡大などが寄与しています。予測期間中に予想される主な動向としては、mRNAベースのワクチンプラットフォームの進化、次世代送達システムの開発、ナノ粒子ワクチン製剤の画期的進歩、ワクチン開発における人工知能の利用、温度管理されたワクチン物流の改善などが挙げられます。

感染症の流行拡大は、予防ワクチン市場の拡大を促進すると予想されます。感染症は、細菌、ウイルス、真菌、寄生虫などの病原性微生物によって引き起こされる病気で、人と人との接触や環境への暴露によって広がる可能性があります。都市化の進展、世界の旅行、抗菌薬耐性などの要因が、これらの疾病の蔓延を加速させ、管理の困難性を高めています。予防ワクチンは、感染症が発生する前に病原体を認識し撃退するよう免疫系を刺激することで、最終的に疾病の発生と伝播を減少させ、感染症を制御する上で重要な役割を果たしています。例えば、2024年7月、オーストラリアの政府機関であるオーストラリア保健福祉研究所（Australian Institute of Health and Welfare）は、2022年、同国では感染症が1万5,770人以上の死亡の原因となっており、下気道感染症がこれらの非通知疾患による死亡の約3分の1を占めていると報告しました。その結果、感染症の負担増が予防ワクチン市場の成長に拍車をかけています。

予防ワクチン市場の企業は、ワクチンの有効性を高め、安全性を改善し、開発期間を短縮し、新興感染症に対する幅広い防御を確保するために、最先端のmRNA技術プラットフォームを含む技術的進歩にますます注力しています。例えば、2025年3月、米国のバイオテクノロジー企業であるModerna Inc.は、新しいCOVID-19ワクチンであるmNEXSPIKE（mRNA-1283）のFDA承認を取得しました。このワクチンは、65歳以上の成人、およびCDCが定義する危険因子を1つ以上有する12～64歳の個人を対象として承認されています。mNEXSPIKEの発売は、次世代mRNAワクチン技術における顕著な進歩であり、以前のものと比較して安定性と保存の容易性が向上しています。この技術革新により、特にサービスが行き届いていない地域や遠隔地でのワクチンの入手・配布が容易になると期待されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の予防ワクチン：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の予防ワクチン市場：成長率分析
• 世界の予防ワクチン市場の実績：規模と成長, 2019-2024
• 世界の予防ワクチン市場の予測：規模と成長, 2024-2029, 2034F
• 世界の予防ワクチン：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の予防ワクチン市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生ワクチンまたは弱毒化ワクチン
• 不活化ワクチン
• トキソイドワクチン
• サブユニットワクチン
• 結合ワクチン
• DNAワクチン
• 組み換えベクターワクチン
• 世界の予防ワクチン市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肺炎球菌
• ポリオウイルス
• 肝炎
• インフルエンザ
• 麻疹
• 風疹
• その他の病気の種類
• 世界の予防ワクチン市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 薬局
• その他の流通チャネル
• 世界の予防ワクチン市場：年齢層別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小児科
• 成人用
• 高齢者
• 世界の予防ワクチン市場生ワクチンまたは弱毒化ワクチンの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 麻疹・おたふく風邪・風疹（MMR）ワクチン
• 水痘（水ぼうそう）ワクチン
• 経口ポリオワクチン（OPV）
• 黄熱病ワクチン
• ロタウイルスワクチン
• カルメット・ゲラン菌（BCG）ワクチン
• 世界の予防ワクチン市場不活化ワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 不活化ポリオウイルスワクチン（IPV）
• A型肝炎ワクチン
• 狂犬病ワクチン
• インフルエンザ（不活化）ワクチン
• 日本脳炎ワクチン
• 世界の予防ワクチン市場トキソイドワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 破傷風トキソイドワクチン
• ジフテリアトキソイドワクチン
• 百日咳ワクチン
• 世界の予防ワクチン市場サブユニットワクチンの種類別細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• B型肝炎ワクチン
• ヒトパピローマウイルス（HPV）ワクチン
• 百日咳（無細胞）ワクチン
• インフルエンザ（組み換えタンパク質）ワクチン
• 世界の予防ワクチン市場結合ワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肺炎球菌結合ワクチン（PCV）
• Hib（インフルエンザ菌b型）ワクチン
• 髄膜炎菌結合ワクチン
• 世界の予防ワクチン市場DNAワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジカウイルスDNAワクチン
• サイトメガロウイルス（CMV）DNAワクチン
• 感染症DNAワクチン
• 世界の予防ワクチン市場組換えベクターワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• エボラワクチン（rVSV-ZEBOV）
• COVID-19組換えベクターワクチン
• デング熱組換えベクターワクチン

第7章 地域別・国別分析

• 世界の予防ワクチン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の予防ワクチン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 予防ワクチン市場：競合情勢
• 予防ワクチン市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi Pasteur SA Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline plc（GSK）
• Takeda Pharmaceutical Company Limited
• Moderna Inc.
• CSL Limited
• Novavax Inc.
• Emergent BioSolutions Inc.
• Dynavax Technologies Corporation
• Serum Institute of India Pvt. Ltd.
• Vaxcyte Inc.
• Bavarian Nordic A/S
• Valneva SE
• Panacea Biotec Ltd.
• Inovio Pharmaceuticals Inc.
• Mitsubishi Tanabe Pharma Corporation
• Afrigen Biologics and Vaccines（Pty）Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 予防ワクチン市場2029：新たな機会を提供する国
• 予防ワクチン市場2029：新たな機会を提供するセグメント
• 予防ワクチン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Preventive vaccines are biological preparations intended to safeguard individuals from infectious diseases by activating the immune system to identify and combat specific pathogens. These vaccines are administered prior to exposure to a disease-causing agent to either prevent infection or lessen its severity. Preventive vaccines serve as a vital component of public health strategies by helping control the transmission of infectious diseases.

The primary categories of preventive vaccines include live or attenuated vaccines, inactivated vaccines, toxoid vaccines, subunit vaccines, conjugate vaccines, DNA vaccines, and recombinant vector vaccines. Live or attenuated vaccines are developed from weakened versions of viruses or bacteria, capable of inducing a strong and long-lasting immune response without causing the actual disease. These vaccines target diseases such as pneumococcal infections, poliovirus, hepatitis, influenza, measles, rubella, and others. They are distributed through various channels including hospitals, clinics, pharmacies, and other medical outlets. The vaccines are formulated for different age groups, including pediatric, adult, and geriatric populations.

The preventive vaccines market research report is one of a series of new reports from The Business Research Company that provides preventive vaccines market statistics, including the preventive vaccines industry global market size, regional shares, competitors with the preventive vaccines market share, detailed preventive vaccines market segments, market trends, and opportunities, and any further data you may need to thrive in the preventive vaccines industry. This preventive vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The preventive vaccines market size has grown strongly in recent years. It will grow from $75.94 billion in 2024 to $81.39 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The historical growth of the market was driven by increased government support, heightened awareness of infectious diseases, expansion of global immunization campaigns, continuous progress in vaccine technologies, and a growing focus on childhood immunizations.

The preventive vaccines market size is expected to see strong growth in the next few years. It will grow to $106.47 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. Contributing factors to this projected growth include a surge in funding for vaccine research, a rising burden of infectious diseases, an uptick in demand for customized vaccines, expanded governmental backing, and wider adoption of cutting-edge vaccine technologies. Key trends anticipated during the forecast period include the evolution of mRNA-based vaccine platforms, the development of next-generation delivery systems, breakthroughs in nanoparticle vaccine formulations, the use of artificial intelligence in vaccine development, and improvements in temperature-controlled vaccine logistics.

The growing prevalence of infectious diseases is expected to drive the expansion of the preventive vaccines market. Infectious diseases are illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites, which can spread through person-to-person contact or environmental exposure. Factors such as increasing urbanization, global travel, and antimicrobial resistance contribute to the accelerated spread and increased difficulty in managing these diseases. Preventive vaccines play a critical role in controlling infectious diseases by stimulating the immune system to recognize and fight off pathogens before infection occurs, ultimately reducing disease incidence and transmission. For example, in July 2024, the Australian Institute of Health and Welfare, a government agency based in Australia, reported that in 2022, infectious diseases were responsible for over 15,770 deaths in the country, with lower respiratory infections accounting for approximately one-third of these non-notifiable disease deaths. Consequently, the rising burden of infectious diseases is fueling the growth of the preventive vaccines market.

Companies in the preventive vaccines market are increasingly focusing on technological advancements, including cutting-edge mRNA technology platforms, to enhance vaccine efficacy, improve safety, accelerate development timelines, and ensure broader protection against emerging infectious disease variants. mRNA technology involves the use of messenger RNA to prompt cells to produce specific proteins that trigger targeted immune responses. For instance, in March 2025, Moderna Inc., a biotechnology firm based in the United States, received FDA approval for mNEXSPIKE (mRNA-1283), a new COVID-19 vaccine. This vaccine is authorized for adults aged 65 and older, as well as individuals aged 12-64 who have one or more CDC-defined risk factors. The release of mNEXSPIKE represents a notable advancement in next-generation mRNA vaccine technology, offering improved stability and ease of storage compared to earlier iterations. This innovation is anticipated to enhance vaccine accessibility and distribution, especially in underserved and remote regions.

In April 2024, European LifeCare Group, a UK-based vaccination services provider, acquired PreventVaccins B.V. for an undisclosed sum. This acquisition enabled European LifeCare Group to expand its presence in the European vaccination market and strengthen its services by incorporating the expertise and operations of PreventVaccins B.V. Based in the Netherlands, PreventVaccins B.V. is a biotechnology company specializing in the development of preventive vaccines targeting infectious diseases.

Major players in the preventive vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, and Afrigen Biologics and Vaccines (Pty) Ltd.

North America was the largest region in the preventive vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in preventive vaccines report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the preventive vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The preventive vaccines market consists of sales of toxoid vaccines, plant-based vaccines, and combination vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Preventive Vaccines Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on preventive vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for preventive vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The preventive vaccines market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Live Or Attenuated Vaccines; Inactivated Vaccines; Toxoid Vaccines; Subunit Vaccines; Conjugate Vaccines; DNA Vaccines; Recombinant Vector Vaccines
• 2) By Disease Type: Pneumococcal; Poliovirus; Hepatitis; Influenza; Measles; Rubella; Other Disease Types
• 3) By Age Group: Pediatric; Adult; Geriatric
• 4) By Distribution Channel: Hospitals; Clinics; Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Live or Attenuated Vaccines: Measles, Mumps, and Rubella (MMR) Vaccine; Varicella (Chickenpox) Vaccine; Oral Polio Vaccine (OPV); Yellow Fever Vaccine; Rotavirus Vaccine; Bacillus Calmette-Guerin (BCG) Vaccine
• 2) By Inactivated Vaccines: Inactivated Poliovirus Vaccine (IPV); Hepatitis A Vaccine; Rabies Vaccine; Influenza (Inactivated) Vaccine; Japanese Encephalitis Vaccine
• 3) By Toxoid Vaccines: Tetanus Toxoid Vaccine; Diphtheria Toxoid Vaccine; Pertussis (whooping cough) Vaccine
• 4) By Subunit Vaccines: Hepatitis B Vaccine; Human Papillomavirus (HPV) Vaccine; Pertussis (acellular) Vaccine; Influenza (recombinant protein) Vaccine
• 5) By Conjugate Vaccines: Pneumococcal Conjugate Vaccine (PCV); Haemophilus influenzae type b (Hib) Vaccine; Meningococcal Conjugate Vaccine
• 6) By DNA Vaccines: Zika Virus DNA Vaccine; Cytomegalovirus (CMV) DNA Vaccine; Infectious Disease DNA Vaccines
• 7) By Recombinant Vector Vaccines: Ebola Vaccine (rVSV-ZEBOV); COVID-19 Recombinant Vector Vaccines; Dengue Recombinant Vector Vaccines
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Sanofi Pasteur SA; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Preventive Vaccines Market Characteristics

3. Preventive Vaccines Market Trends And Strategies

4. Preventive Vaccines Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Preventive Vaccines Growth Analysis And Strategic Analysis Framework

• 5.1. Global Preventive Vaccines PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Preventive Vaccines Market Growth Rate Analysis
• 5.4. Global Preventive Vaccines Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Preventive Vaccines Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Preventive Vaccines Total Addressable Market (TAM)

6. Preventive Vaccines Market Segmentation

• 6.1. Global Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Live Or Attenuated Vaccines
• Inactivated Vaccines
• Toxoid Vaccines
• Subunit Vaccines
• Conjugate Vaccines
• DNA Vaccines
• Recombinant Vector Vaccines
• 6.2. Global Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pneumococcal
• Poliovirus
• Hepatitis
• Influenza
• Measles
• Rubella
• Other Disease Types
• 6.3. Global Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Pharmacies
• Other Distribution Channels
• 6.4. Global Preventive Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric
• Adult
• Geriatric
• 6.5. Global Preventive Vaccines Market, Sub-Segmentation Of Live or Attenuated Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Measles, Mumps, and Rubella (MMR) Vaccine
• Varicella (Chickenpox) Vaccine
• Oral Polio Vaccine (OPV)
• Yellow Fever Vaccine
• Rotavirus Vaccine
• Bacillus Calmette-Guerin (BCG) Vaccine
• 6.6. Global Preventive Vaccines Market, Sub-Segmentation Of Inactivated Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inactivated Poliovirus Vaccine (IPV)
• Hepatitis A Vaccine
• Rabies Vaccine
• Influenza (Inactivated) Vaccine
• Japanese Encephalitis Vaccine
• 6.7. Global Preventive Vaccines Market, Sub-Segmentation Of Toxoid Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tetanus Toxoid Vaccine
• Diphtheria Toxoid Vaccine
• Pertussis (whooping cough) Vaccine
• 6.8. Global Preventive Vaccines Market, Sub-Segmentation Of Subunit Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatitis B Vaccine
• Human Papillomavirus (HPV) Vaccine
• Pertussis (acellular) Vaccine
• Influenza (recombinant protein) Vaccine
• 6.9. Global Preventive Vaccines Market, Sub-Segmentation Of Conjugate Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pneumococcal Conjugate Vaccine (PCV)
• Haemophilus influenzae type b (Hib) Vaccine
• Meningococcal Conjugate Vaccine
• 6.10. Global Preventive Vaccines Market, Sub-Segmentation Of DNA Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Zika Virus DNA Vaccine
• Cytomegalovirus (CMV) DNA Vaccine
• Infectious Disease DNA Vaccines
• 6.11. Global Preventive Vaccines Market, Sub-Segmentation Of Recombinant Vector Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ebola Vaccine (rVSV-ZEBOV)
• COVID-19 Recombinant Vector Vaccines
• Dengue Recombinant Vector Vaccines

7. Preventive Vaccines Market Regional And Country Analysis

• 7.1. Global Preventive Vaccines Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Preventive Vaccines Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Preventive Vaccines Market

• 8.1. Asia-Pacific Preventive Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Preventive Vaccines Market

• 9.1. China Preventive Vaccines Market Overview
• 9.2. China Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Preventive Vaccines Market

• 10.1. India Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Preventive Vaccines Market

• 11.1. Japan Preventive Vaccines Market Overview
• 11.2. Japan Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Preventive Vaccines Market

• 12.1. Australia Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Preventive Vaccines Market

• 13.1. Indonesia Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Preventive Vaccines Market

• 14.1. South Korea Preventive Vaccines Market Overview
• 14.2. South Korea Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Preventive Vaccines Market

• 15.1. Western Europe Preventive Vaccines Market Overview
• 15.2. Western Europe Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Preventive Vaccines Market

• 16.1. UK Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Preventive Vaccines Market

• 17.1. Germany Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Preventive Vaccines Market

• 18.1. France Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Preventive Vaccines Market

• 19.1. Italy Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Preventive Vaccines Market

• 20.1. Spain Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Preventive Vaccines Market

• 21.1. Eastern Europe Preventive Vaccines Market Overview
• 21.2. Eastern Europe Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Preventive Vaccines Market

• 22.1. Russia Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Preventive Vaccines Market

• 23.1. North America Preventive Vaccines Market Overview
• 23.2. North America Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Preventive Vaccines Market

• 24.1. USA Preventive Vaccines Market Overview
• 24.2. USA Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Preventive Vaccines Market

• 25.1. Canada Preventive Vaccines Market Overview
• 25.2. Canada Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Preventive Vaccines Market

• 26.1. South America Preventive Vaccines Market Overview
• 26.2. South America Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Preventive Vaccines Market

• 27.1. Brazil Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Preventive Vaccines Market

• 28.1. Middle East Preventive Vaccines Market Overview
• 28.2. Middle East Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Preventive Vaccines Market

• 29.1. Africa Preventive Vaccines Market Overview
• 29.2. Africa Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Preventive Vaccines Market Competitive Landscape And Company Profiles

• 30.1. Preventive Vaccines Market Competitive Landscape
• 30.2. Preventive Vaccines Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi Pasteur SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Preventive Vaccines Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc (GSK)
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Moderna Inc.
• 31.4. CSL Limited
• 31.5. Novavax Inc.
• 31.6. Emergent BioSolutions Inc.
• 31.7. Dynavax Technologies Corporation
• 31.8. Serum Institute of India Pvt. Ltd.
• 31.9. Vaxcyte Inc.
• 31.10. Bavarian Nordic A/S
• 31.11. Valneva SE
• 31.12. Panacea Biotec Ltd.
• 31.13. Inovio Pharmaceuticals Inc.
• 31.14. Mitsubishi Tanabe Pharma Corporation
• 31.15. Afrigen Biologics and Vaccines (Pty) Ltd.

32. Global Preventive Vaccines Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Preventive Vaccines Market

34. Recent Developments In The Preventive Vaccines Market

35. Preventive Vaccines Market High Potential Countries, Segments and Strategies

• 35.1 Preventive Vaccines Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Preventive Vaccines Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Preventive Vaccines Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer